We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > lupus nephritis

News List

EC clears GSK's Benlysta for lupus nephritis pharmatimes
May 07, 2021
The European Commission approved expanded use of GlaxoSmithKline’s intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis (LN).
Catalent, Aurinia Ink LUPKYNIS Commercial Supply Pact contractpharma
February 20, 2021
Catalent has signed a multi-year commercial supply agreement with Aurinia Pharmaceuticals for LUPKYNIS (voclosporin), a drug to treat adult patients with lupus nephritis (LN).
Voclosporin approved by FDA to treat lupus nephritis europeanpharmaceuticalreview
January 26, 2021
The FDA has approved Aurinia Pharmaceuticals’ LupkynisTM(voclosporin) for the treatment of lupus nephritis, alongside standard-of-care.
GSK gets FDA nod for Benlysta to treat adult patients with active lupus nephritis pharmaceutical-business-review
December 21, 2020
GlaxoSmithKline (GSK) has secured approval from the US Food and Drug Administration (FDA) for its Benlysta (belimumab) to treat adult patients with active lupus nephritis (LN) who are securing standard therapy.